Check-Cap Ltd.(以下“会社”または“Check-Cap”)(ナスダックコード:CHEK)、C-開発を推進する臨床段階医療診断会社(ナスダックコード:CHEKZ)は、ポリープが結腸直腸癌に...
ログインすると全部閲覧できます。
ログイン
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today issued the following letter from its chief executive officer, Alex Ovadia, to its shareholders and the investment community:
Dear Check-Cap Shareholders,
We have greatly appreciated your support throughout 2021, a year during which we have continued our progress as we prepare to initiate our U.S. pivotal study of C-Scan, including strengthening our...
Check-Cap Ltd.(以下“会社”または“Check-Cap”)(ナスダックコード:CHEK)、C-開発を推進する臨床段階医療診断会社(ナスダックコード:CHEKZ)は、ポリープが結腸直腸癌に...
ブラウザの共有ボタンを使って、このページを友人と共有することができます。